Advertisement

Anticoagulant Monitoring

  • James M. Wilson
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)

Abstract

Inhibition of normal hemostatic mechanisms is the cornerstone of medical therapy for many cardiovascular diseases. Inhibition of thrombus growth and development is the goal of antithrombotic therapy, yet it results in an increased risk of spontaneous hemorrhage, which may result in substantial morbidity and even death. Therefore, if antithrombotic therapy is to be of value, a delicate equilibrium must be maintained between prevention of pathologic thrombosis and an excess risk of life-threatening hemorrhage.

Keywords

International Normalize Ratio Prothrombin Time Tissue Factor Partial Thromboplastin Time Thrombin Generation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landefield CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82:703, 1987.Google Scholar
  2. 2.
    Hoppensteadt DA, Waling JM, Fareed J. Validity of serine protease inhibition tests in the evaluation and monitoring or the effect of heparin and its fractions. Semin Thromb Hemostas 11:112, 1985.Google Scholar
  3. 3.
    Holm HA, Abildgaard U, Kalvenes S, Anderssen N, Anker E, Arnesen KE, Blikom D, Drivenes A. The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays. Acta Med Stand 216:287, 1984.Google Scholar
  4. 4.
    Holm HA, Abildgaard U, Larsen ML, Kalvenes S. Monitoring of heparin therapy: Should heparin assays also reflect the patients antithrombin concentration? Thromb Res 46:669, 1987.PubMedGoogle Scholar
  5. 5.
    van den Besselaar AMHP, Meruwisse-Braun J, Bertina RM. Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 63:16, 1990.PubMedGoogle Scholar
  6. 6.
    Manucci PM, Botasso B, Tripodi A, Bianchi BA. Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants. Thromb Haemost 66:741, 1991.Google Scholar
  7. 7.
    Hoek JA, Nurmohamed MT, tenCate JW, Buller HR, Knipscheer HC, Hamelynck KJ, Marti RK, Stur KA. Thrombin-antithrombin III complexes in the prediction of deep vein thrombosis following total hip replacement. Thromb Haemost 62:1050, 1989PubMedGoogle Scholar
  8. 8.
    Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324, 1972.PubMedCrossRefGoogle Scholar
  9. 9.
    Congdon JE, Kardinal C, Wallin JD. Monitoring heparin therapy on hemodialysis. JAMA 226:1529, 1973.PubMedGoogle Scholar
  10. 10.
    Thompson JM. The implementation of international normalized ratios for standardization of the prothrombin time in oral anticoagulant control. In Thompson JM (ed). Blood Coagulation and Hemostatis. New York: Churchill Livingstone, 1991:261.Google Scholar
  11. 11.
    Bounameaux H, Market GA, Lämmle B, Eichlisberger R, Duckert F. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. Am J Clin Pathol 74:68, 1980.PubMedGoogle Scholar
  12. 12.
    Alving BM. Lupus anticoagulants, anticardiolipin antibodies, and the antiphospholipid syndrome. In Loscalzo J, Schaeffer AI (eds). Thrombosis and Hemorrhage. Boston: Blackwell Scientific, 1994:749.Google Scholar
  13. 13.
    Alson JD, Pennell BJ. Automated coagulation systems. In Haven MC, Tetrault GA, Schenken JR (eds). Laboratory Instrumentation Systems, 4th ed. New York: Van Nostrand Reinhold, 1995:391.Google Scholar
  14. 14.
    Hemker HC, Kessels H. Feedback mechanisms in coagulation. Haemostasis 21:189, 1991.PubMedGoogle Scholar
  15. 15.
    Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 60:457, 1988.PubMedGoogle Scholar
  16. 16.
    Hemker HC, Beguin S. Mode of action of heparin and related drugs. Semin Thromb Hemost 17(Suppl. 1):29, 1991.PubMedGoogle Scholar
  17. 17.
    Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12:1111, 1992.PubMedGoogle Scholar
  18. 18.
    Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajckman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 243:579, 1987.PubMedGoogle Scholar
  19. 19.
    Jesty J. Interaction of feedback control and product inhibition in the activation of factor X by factors IXa and VIII. Haemostasis 21:208, 1991.PubMedGoogle Scholar
  20. 20.
    Willems GM, Lindhout T, Hermens WT, Hemker HC. Simulation model for thrombin generation in plasma. Haemostasis 21:197, 1991.PubMedGoogle Scholar
  21. 21.
    Mann KG, Krishnaswamy S, Lawson JH. Surfacedependent hemostasis. Semin Hematol 29:213, 1992.PubMedGoogle Scholar
  22. 22.
    Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 254:10952, 1979.PubMedGoogle Scholar
  23. 23.
    Kane WH, Davie EW. Blood coagulation factors V and VIII, structural and functional similarities and this relationship to hemorrhagic and thrombotic disorders. Blood 71:539, 1988.PubMedGoogle Scholar
  24. 24.
    Rapaport SI, Schiffman S, Patch MJ, Ames SB. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood 21:221, 1963.PubMedGoogle Scholar
  25. 25.
    Pieters J, Lindhout T, Hemker HC. In-situ generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 74:1021, 1989.PubMedGoogle Scholar
  26. 26.
    Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant activity while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460, 1986.PubMedGoogle Scholar
  27. 27.
    Tracy PB, Nesheim ME, Mann KG. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 256:743, 1981.PubMedGoogle Scholar
  28. 28.
    Bevers EM, Comfurius P, van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prochrombin converting activity and the exposure of phosphatidyl serine at the outer surface of platelets. Eur J Biochem 122:429, 1982.PubMedGoogle Scholar
  29. 29.
    McGee MP, Li LC. Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages. J Biol Chem 266:8079, 1991.PubMedGoogle Scholar
  30. 30.
    Tracy PB, Rohrback MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258:7264, 1983.PubMedGoogle Scholar
  31. 31.
    Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem 260:2119, 1985.PubMedGoogle Scholar
  32. 32.
    Robinson RA, Worfolk L, Tracy PB. Endotoxin enhances the expression of monocyte prothrombinase activity. Blood 79:406, 1992.PubMedGoogle Scholar
  33. 33.
    Altieri D. Coagulation assembly on leukocytes in transmembrane signaling and cell adhesion. Blood 81:569, 1993.PubMedGoogle Scholar
  34. 34.
    Miale JB. Laboratory Medicine: Hematology, 4th ed. St. Louis, MO: Mosby, 1972:1054.Google Scholar
  35. 35.
    Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and jaundice. Am J Med Sci 190:501, 1935.Google Scholar
  36. 36.
    Biggs R, MacFarlane RG. Reaction of hemophilic plasma to thromboplastin. J Clin Pathol 4:445, 1951.PubMedGoogle Scholar
  37. 37.
    Roberts HR, Eberst ME. Other coagulation deficiencies. In Loscalzo J, Schaeffer AI (eds). Thrombosis and Hemorrhage. Boston: Blackwell Scientific, 1994:701.Google Scholar
  38. 38.
    Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 29:170, 1992.PubMedGoogle Scholar
  39. 39.
    Nemerson Y. Tissue factor and hemostasis. Blood 71:1, 1988.PubMedGoogle Scholar
  40. 40.
    Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734, 1993.PubMedGoogle Scholar
  41. 41.
    Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence of factor IX concentrates and persistence in the circulation after infusion. Blood 53:828, 1979.PubMedGoogle Scholar
  42. 42.
    Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 88:2015, 1993.PubMedGoogle Scholar
  43. 43.
    Sharma GVRK, Lapsley O, Vita JA, Sharma S, Cocao E, Adelman B, Loscalzo J. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 72:1357, 1993.PubMedGoogle Scholar
  44. 44.
    Palmer RN, Kessler CM, Gralink HR. Warfarin anticoagulation: Difficulties in interpretation of the prothrombin time. Thromb Res 25:125, 1982.PubMedGoogle Scholar
  45. 45.
    Peterson P, Gottfried EL. The effects of inaccurate blood sample volume on prothrombin time and activated partial thromboplastin time (aPTT). Thromb Haemost 47:101, 1982.PubMedGoogle Scholar
  46. 46.
    Poller L, Thompson JM. Problems of international normalized ratio implementation in prothrombin time standardization. In Poller I. (ed). Current Advances in Blood Coagulation, No. 6. Churchill Livingstone, 1993:155.Google Scholar
  47. 47.
    Kirkwood TBL. Combination of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 49:238, 1983.PubMedGoogle Scholar
  48. 48.
    Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulant therapy. Arch Intern Med 152:278, 1992.PubMedGoogle Scholar
  49. 49.
    Hirsh J, Levine M. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America. Thromb Haemost 59:129, 1988.PubMedGoogle Scholar
  50. 50.
    Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 329:696, 1993.PubMedGoogle Scholar
  51. 51.
    Poller L, Taberner DA. Dosage and control of oral anticoagulants: An international survey. Br J Haematol 51:479, 1982.PubMedGoogle Scholar
  52. 52.
    Hull R, Hirsh J, Jay R, Carter C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockleford P. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis. N Engl J Med 307:1676, 1982.PubMedCrossRefGoogle Scholar
  53. 53.
    Furie B, Liebman HA, Blanchard RA, Coleman M, Kruger SF, Furie BC. Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy. Blood 64:445, 1984.PubMedGoogle Scholar
  54. 54.
    Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: Significance of a vitamin K epoxide reductase inhibition. Biochemistry 17:1371, 1978.PubMedGoogle Scholar
  55. 55.
    Kornberg A, Francis CW, Pellegrini VD, Gabriel KR, Marder VJ. Comparison of native prothrombin antigen with the prothrombin time tor monitoring oral anticoagulant prophylaxis. Circulation 88:454, 1993.PubMedGoogle Scholar
  56. 56.
    Furie B, Dinguid CF, Jacobs M, Dinguid DL, Furie BC. Randomized prospective trial comparing native prothrombin antigen with the prothrombin time for monironng oral anticoagulant therapy. Blood 75:344, 1990.PubMedGoogle Scholar
  57. 57.
    Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 145:495, 1913.Google Scholar
  58. 58.
    Pitney WR. Control of heparin therapy. Br Med J 4:139, 1970.PubMedGoogle Scholar
  59. 59.
    Peerschke EIB. Platelet membranes and receprors. In Loscalzo J, Schafer AI (eds). Thrombosis and Hemorrhage Blackwell Scientific, Boston 1994:247.Google Scholar
  60. 60.
    Bauer JD, Ackerman PG, Toro G (eds). Bray’s Clinical Laboratory Methods, 7th ed. St. Louis, MO: CV Mosby, 1968:210.Google Scholar
  61. 61.
    Owen C Jr, Mann F, Hum M, Stickney J. Evaluation of disorders of blood coagulation in the clinical laboratory. Am J Clin Pathol 25:1417, 1955.PubMedGoogle Scholar
  62. 62.
    Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one stage clotting tests. J Lab Clin Med 41:637, 1953.PubMedGoogle Scholar
  63. 63.
    Nye SW, Graham JB, Brinkhous KM. The partial thromboplastin time as a screening test for the detection of latent bleeders. Am J Med Sci 243:279, 1962.PubMedGoogle Scholar
  64. 64.
    Quick A, Geppert M. Screening for bleeding states — the partial thromboplastin test. Am J Clin Pathol 40:465, 1963.PubMedGoogle Scholar
  65. 65.
    Goulian M, Beck WS. The partial thromboplastin time test. Modification of the procedure and study of the sensitivity and optimal conditions. Am J Clin Pathol 44:97, 1965.Google Scholar
  66. 66.
    Sawitsky A, Boklan BF. Gauchers disease and coagularion factors. Ann Intern Med 77:150, 1972.PubMedGoogle Scholar
  67. 67.
    Mant MJ, Hirsh J, Pineo GF, Luke KH. Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Br J Haematol 24:725, 1973.PubMedGoogle Scholar
  68. 68.
    Brinkhous KM, Langdell RD, Penick GD, Graham JB, Wagner RH. Newer approaches to the study of hemophilia and hemophilioid states. JAMA 154:481, 1954.Google Scholar
  69. 69.
    Hougie C, Barrow EM, Graham JB. Stuart clotting defect. Segregation of an hereditary hemorrhagic state from the heterogenous group heretofore called “STABLE factor” (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 36:485, 1957.PubMedGoogle Scholar
  70. 70.
    Hathaway WS, Belhasen LP, Hathaway HS. Evidence tor a new plasma thromboplastin factor. Case report, coagulation studies and physicochemical properties. Blood 26:521, 1965.PubMedGoogle Scholar
  71. 71.
    Sairo H, Ratnoff OD, Waldman R, Abraham JP. Fitzgerald trait — deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability (PF-DIL). J Clin Invest 55:1082, 1975.Google Scholar
  72. 72.
    Colman RN, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait — human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of Hageman factor dependent pathways. J Clin Invest 56:1650, 1975.PubMedGoogle Scholar
  73. 73.
    Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait — deficiency of human plasma kininogen. J Clin Invest 56:1663, 1975.PubMedGoogle Scholar
  74. 74.
    Revak SD, Cochrane CG. Hageman factor: Its structure and modes of activation. Thromb Haemost 35:570, 1976.PubMedGoogle Scholar
  75. 75.
    Hattersly PG, Hayse D. The effect of increased contact activation time on the activated partial thromboplastin time. Am J Clin Pathol 66:479, 1976.Google Scholar
  76. 76.
    Ygge J. Changes in blood coagulation and fibrinolysis during the post operative period. Am J Surg 119:225, 1970.PubMedGoogle Scholar
  77. 77.
    Davidson E, Tomlin S. The levels of plasma coagulation factors in the post operative period. Thromb Diath Hemorrh 10:81, 1963.Google Scholar
  78. 78.
    Pechet L, Alexander B. Increased clotting factors in pregnancy. N Engl J Med 265:1093, 1961.PubMedCrossRefGoogle Scholar
  79. 79.
    Bonnar J, McNicol GP, Douglas AS. Coagulation and fibrinolytic mechanisms during and after normal childbirth. Br Med J 2:200, 1970.PubMedCrossRefGoogle Scholar
  80. 80.
    Korsan-Bengsten K, Wilhelmsen L, Elmfeldt D, Tibblen G. Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample. Atherosclerosis 16:83. 1972.Google Scholar
  81. 81.
    Edson JR, Kiwit W, White JG. Kaolin partial thromboplastin time: High levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 70:463, 1967.PubMedGoogle Scholar
  82. 82.
    Hirsh J. Heparin. N Engl J Med 324:1565, 1991.PubMedCrossRefGoogle Scholar
  83. 83.
    Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324, 1972.PubMedCrossRefGoogle Scholar
  84. 84.
    Spector I, Corn M. Control of heparin therapy with activated partial thromboplastin times. JAMA 201:157, 1967.Google Scholar
  85. 85.
    Hull RD, Raskob GE, Hirsh J, Jay RM, Leclere JR, Geerts W, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109, 1986.PubMedCrossRefGoogle Scholar
  86. 86.
    Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsbery JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 322:1260, 1990.PubMedCrossRefGoogle Scholar
  87. 87.
    Theroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasia KJ, de Guise P. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 319:1105, 1988.PubMedCrossRefGoogle Scholar
  88. 88.
    Hsai J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Am J Cardiol 66:1412, 1990.Google Scholar
  89. 89.
    de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Bescos LL, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomized double-blind European Cooperative Study Group trial. Br Heart J 67:122, 1992.PubMedGoogle Scholar
  90. 90.
    Cuccia C, Volterrani M, Volpini M, Musmeci G, Scalvini S, Campana M, Leonzi O, Niccoli L, Pagani M. Relationship between anticoagulation level, ischemic events, and angiographic characteristics of infarct-related artery following streptokinase in patients with acute myocardial infarction (abstr). J Am Coll Cardiol 19:92, 1992.Google Scholar
  91. 91.
    Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 89:1449, 1994.PubMedGoogle Scholar
  92. 92.
    Mattox KC, Guinn GA, Rubio PA, Beall AC Jr. Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations. Ann Thorac Surg 19:634, 1975.PubMedCrossRefGoogle Scholar
  93. 93.
    Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circularion: II. J Thorac Cardiovasc Surg 69:685, 1975.PubMedGoogle Scholar
  94. 94.
    Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 26:231, 1978.PubMedCrossRefGoogle Scholar
  95. 95.
    Dougherty KG, Gaos CM, Bush HS, Leachman R, Ferguson JJ. Activated clotting times and activated partial thromboplastin rimes in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 26:260, 1992.PubMedGoogle Scholar
  96. 96.
    Ogilby JD, Kopelman HA, Klein LW, Agrawal JB. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 18:206, 1989.PubMedGoogle Scholar
  97. 97.
    Colman RN, Oxley L, Gianrusa P. Statistical comparison of the automated activated partial thromboplastin time and the clotting time in the regulation of heparin therapy. Am J Clin Pathol 53:904, 1970.Google Scholar
  98. 98.
    Schriever HG, Epstein SE, Mintz MD. Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood clotting time and an automated coagulation time. Am J Clin Pathol 60:323, 1973.PubMedGoogle Scholar
  99. 99.
    Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 61:25, 1989.PubMedGoogle Scholar
  100. 100.
    Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet rich thrombi. Role of platelet factor 4. Circulation 89:1523, 1994.PubMedGoogle Scholar
  101. 101.
    Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors. J Clin Invest 86:385, 1990.PubMedGoogle Scholar
  102. 102.
    Fey MF, Lang M, Furlan M, Beck EA. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays. Thromb Haemost 58:853, 1987.PubMedGoogle Scholar
  103. 103.
    de Boer A, van Riel L, den Ottolander GJ. Measurements of antithrombin III, X2-macroglobulin and X1 antitrypsin in patients with deep venous thrombosis and pulmonary embolism. Thromb Res 15:17, 1979.PubMedGoogle Scholar
  104. 104.
    Marciniak E, Gockemen J. Heparin-induced decrease in circulating antithrombin III. Lancet 2:581, 1978.Google Scholar
  105. 105.
    Smith LG, Kitchens CS. A comparison between two commercially available activators for determining the partial thromboplastin time. Arch Pathol Lab Med 109:243, 1985.PubMedGoogle Scholar
  106. 106.
    Lenahan JG, Phillips GE. Some variables which influence the activated partial thromboplastin time assay. Clin Chem 12:269, 1966.PubMedGoogle Scholar
  107. 107.
    Bjoinsson TD, Nash PV. Variability in heparin sensitivity of APTT reagents. Am J Clin Pathol 86:199, 1986.Google Scholar
  108. 108.
    Barrowcliffe TW, Gray E. Studies of phospholipid reagents used in coagulation. II. Factors influencing sensitivity to heparin. Thromb Haemost 46:634, 1981.PubMedGoogle Scholar
  109. 109.
    Gawoski JM, Arkin CF, Bovill T, Brandt J, Rock WA, Triplett DA. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists survey specimens. Arch Parhol Lab Med 111:785, 1987.Google Scholar
  110. 110.
    Brandt JT, Tuplett DA. Laboratory monitoring of heparin: Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 765:530, 1981.Google Scholar
  111. 111.
    Reed SV, Haddon ME, Denson KWE. An attempt to standardize the aPTT for heparin monitoring using the P.T. ISI/INR system of calibration. Results of a 13 center study. Thromb Res 74:515, 1994.PubMedGoogle Scholar
  112. 112.
    Green D, Ts’ao CH, Reynolds N, Kahn D, Kohl H, Cohen I. In vitro studies of a new synthetic thrombin inhibitor. Thromb Res 37:145, 1985.PubMedGoogle Scholar
  113. 113.
    Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced plarelet activation of a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 75:399, 1990.PubMedGoogle Scholar
  114. 114.
    Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet rich arterial thrombosis by selective thrombin inhibition. Circulation 81:219, 1990.PubMedGoogle Scholar
  115. 115.
    Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro46-6240 in experimental arterial thrombosis. Circulation 91:1568, 1995.PubMedGoogle Scholar
  116. 116.
    Hattersly PG. Activated coagulation time of whole blood. JAMA 196:437, 1966.Google Scholar
  117. 117.
    Hemker HC, Béguin S. The mode of action of heparins in vitro and in vivo. In Lane et al. (eds). Heparin and Related Polysaccharides. New York: Plenum Press, 1992:221.Google Scholar
  118. 118.
    Ferguson JJ. All ACT’s are not the same. THI J 19:1, 1992.Google Scholar
  119. 119.
    Avendaño A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal angioplasty. J Am Coll Cardiol 23:907, 1994.PubMedCrossRefGoogle Scholar
  120. 120.
    Hattersly P. Program report: The activated coagulation time of whole blood (ACT). Am J Clin Pathol 66:899, 1976.Google Scholar
  121. 121.
    Gravlee GP, Whitaker CL, Mark LJ, Rogers AT, Royster RL, Harrison GA. Baseline activated clotting time should be measured after surgical incision. Anesth Analg 71:549, 1990.PubMedGoogle Scholar
  122. 122.
    Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous coronary angioplasty, Cathet Cardiovasc Diagn 34:1, 1995.PubMedGoogle Scholar
  123. 123.
    van Putten J, Ruit VDM, Beunis M, Hemker HC. Heparin neutralization during collection and processing of blood inhibited by pyridoxal 5’-phosphate. Haemostasis 14:253, 1984.PubMedGoogle Scholar
  124. 124.
    Blakely JA. A rapid bedside method for the control of heparin therapy. Can Med Assoc J 99:1072, 1968.PubMedGoogle Scholar
  125. 125.
    Vacek JL, Hibiya K, Rosamond TL, Kramer PH, Beauchamp GD. Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines. Am J Cardiol 68:557, 1991.PubMedGoogle Scholar
  126. 126.
    Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Barnes P, Cox JL, Lappas DG. On site prothrombin time, activated partial thromboplastin time, and platelet count. A comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 80:338, 1994.PubMedGoogle Scholar
  127. 127.
    Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation moniroring in heparin-treated patients with active thromboembolic disease: A coronary care unit experience. Am Heart J 128:719, 1994.PubMedGoogle Scholar
  128. 128.
    Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. The effect of platelet glycoprotein IIb/IIIa in tegrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional a therectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 75:559, 1995.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • James M. Wilson

There are no affiliations available

Personalised recommendations